MARKET

NARI

NARI

Inari Medical, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

60.02
+3.80
+6.76%
After Hours: 60.02 0 0.00% 18:47 08/03 EDT
OPEN
57.10
PREV CLOSE
56.22
HIGH
61.34
LOW
55.58
VOLUME
427.40K
TURNOVER
--
52 WEEK HIGH
61.76
52 WEEK LOW
39.55
MARKET CAP
2.77B
P/E (TTM)
714.52
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NARI stock price target is 53.67 with a high estimate of 60.00 and a low estimate of 49.00.

EPS

NARI News

More
Inari Medical to Present at the Canaccord Genuity 40th Annual Growth Conference
IRVINE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) today announced the company will be participating in the upcoming Canaccord Genuity 40th Annual Virtual Growth Conference. Inari’s management is scheduled to presen
GlobeNewswire · 5d ago
Inari Medical to Announce Second Quarter 2020 Financial Results
IRVINE, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) today announced it will release financial results for the second quarter of 2020 after market close on Tuesday, August 11, 2020. On the same day, Inari will host a c
GlobeNewswire · 6d ago
Inari Medical (NARI): Strong Growth And Abundant Potential
Brown Advisory recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Mid-Cap Growth Fund posted a return of 31.64% for the quarter, outperforming its benchmark, the Russell Midcap Growth Index which returned 30.26% in the sa
Insider Monkey · 07/24 14:06
The Daily Biotech Pulse: Blueprint, Roche Ink $1.7B Cancer Drug Collaboration, INmune's Positive Alzheimer's Readout, Edwards, Abbott Settle Patent Lawsuits
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13)
Benzinga · 07/14 12:04
Canaccord Genuity Initiates Coverage On Inari Medical with Buy Rating, Announces Price Target of $60
Canaccord Genuity initiates coverage on Inari Medical (NASDAQ:NARI) with a Buy rating and announces Price Target of $60.
Benzinga · 06/22 14:39
Canaccord Genuity Initiates Coverage On Inari Medical with Buy Rating, Announces Price Target of $60
Canaccord Genuity initiates coverage on Inari Medical (NASDAQ:NARI) with a Buy rating and announces Price Target of $60.
Benzinga · 06/19 11:51
Wells Fargo Initiates Coverage On Inari Medical with Equal-Weight Rating, Announces Price Target of $49
Wells Fargo initiates coverage on Inari Medical (NASDAQ:NARI) with a Equal-Weight rating and announces Price Target of $49.
Benzinga · 06/16 09:42
Morgan Stanley Initiates Coverage On Inari Medical with Equal-Weight Rating, Announces Price Target of $52
Morgan Stanley initiates coverage on Inari Medical (NASDAQ:NARI) with a Equal-Weight rating and announces Price Target of $52.
Benzinga · 06/16 09:41

Industry

Medical Equipment, Supplies & Distribution
+0.78%
Healthcare Equipment & Supplies
+1.20%

Hot Stocks

Symbol
Price
%Change

About NARI

Inari Medical, Inc. is a commercial-stage medical device company. The Company is focused on developing products to treat venous diseases. The Company’s product offering consists of two minimally-invasive, catheter-based mechanical thrombectomy devices. The Company built two products for the treatment of venous thromboembolism (VTE deep vein thrombosis) and pulmonary embolism (PE). The Company provides two products ClotTriever and FlowTriever. ClotTriever product is Food and Drug Administration (FDA) cleared for the removal of clot from peripheral blood vessels and is used to deep vein thrombosis (DVT). FlowTriever product is thrombectomy system FDA cleared for the treatment of pulmonary embolism (PE). Its product ClotTriever and FlowTriever offer clinical benefits and provides safety to limit effectiveness of thrombolytic drugs and repurposed arterial devices for the treatment of VTE.
More

Webull offers kinds of Inari Medical Inc stock information, including NASDAQ:NARI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NARI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NARI stock methods without spending real money on the virtual paper trading platform.